HCW Biologics says licensee WY Biotech will likely miss $7M upfront payment; negotiations ongoing

HCW Biologics Inc.

WY Biotech likely won't meet Sept 30, 2025 deadline for $7.0M upfront license fee under exclusive agreement.
WY Biotech has not finalized CDMO and investor agreements, delaying payment as previously reported.
Company and WY Biotech are negotiating potential further revisions and additions to the license agreement.
Delay follows earlier extension from July 18, 2025; no revised payment date has been set.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.